Skip to main content
Lonza Group AG logo

Lonza Group AG — Investor Relations & Filings

Ticker · LONN ISIN · CH1255014495 LEI · 549300EFW4H2TCZ71055 SW Manufacturing
Filings indexed 137 across all filing types
Latest filing 2022-07-22 Earnings Release
Country CH Switzerland
Listing SW LONN

About Lonza Group AG

https://www.lonza.com/

Lonza Group AG is a global contract development and manufacturing organization (CDMO) that partners with the pharmaceutical, biotech, and nutrition industries. The company provides integrated services that span the entire product lifecycle, from early-phase research and process development to custom, large-scale commercial manufacturing. Its expertise covers a wide range of therapeutic modalities, including mammalian and microbial biopharmaceuticals, small molecules, cell and gene therapies, highly potent active pharmaceutical ingredients (APIs), peptides, and bioconjugates. By combining advanced scientific and technological insights with world-class manufacturing and regulatory expertise, Lonza supports its customers in developing and commercializing innovative medicines and health products for patients worldwide.

Recent filings

Filing Released Lang Actions
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
Earnings Release Classification · 100% confidence The document is explicitly titled 'Ad-hoc announcement pursuant to Art. 53 LR' and details the company's financial performance for the 'First Half' (H1 2022), including sales, CORE EBITDA, CAPEX, and divisional overviews. This structure—a summary press release announcing period results before the full report—is characteristic of an Earnings Release (ER). Although it references the 'Half-Year 2022 Report' and 'Presentation', the document itself is the initial announcement of the results, not the full report or a mere announcement of publication. Since it covers a period shorter than a year ('H1 2022'), it is more specific than a general Earnings Release (ER) and aligns perfectly with the definition of an Interim/Quarterly Report (IR), which covers comprehensive financial results for a period shorter than a year. However, in many regulatory contexts, the initial press release summarizing the period's performance is classified as an Earnings Release (ER), while the comprehensive filing (like a 10-Q equivalent) is the Interim Report (IR). Given the format is a news release summarizing key figures and outlook confirmation, ER is the most appropriate classification for this initial disclosure, even though it covers a half-year period. The document is substantial (7858 chars) and contains detailed financial summaries, making it more than just a brief announcement of a report (RPA/RNS). H1 2022
2022-07-22 English
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and explicitly reports on 'H1 2022' performance, including sales, CORE EBITDA margin, and CAPEX figures. It provides key financial highlights for the first half of the year and confirms the Group Outlook for 2022 and Mid-Term Guidance 2024. This structure—a concise announcement detailing financial results for a period shorter than a full year (H1)—is characteristic of an Interim/Quarterly Report announcement, which maps to the 'Interim / Quarterly Report' definition (IR). Although it contains highlights, the depth of divisional review suggests it is more than just a brief Earnings Release (ER). It is not the full report itself, but the official announcement of those results. H1 2022
2022-07-22 English
Lonza erzielt im ersten Halbjahr 2022 ein solides Ergebnis mit einem Umsatzwachstum von 16.8% (kWk) und einer Kern-EBITDA-Marge von 33.1%
Earnings Release Classification · 100% confidence The document is explicitly titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and is dated July 22, 2022. It summarizes key financial results for the first half of 2022 (Umsatzwachstum von 16.8%, Kern-EBITDA-Marge von 33.1%) and confirms the outlook for 2022 and 2024. This structure—a brief, timely announcement of key periodic financial results—fits the definition of an Earnings Release (ER). Although it mentions the full 'Halbjahresbericht 2022' (Interim/Half-Year Report) is available via a link, the document itself is the initial press release summarizing those results, not the comprehensive report (which would be classified as IR). It is too detailed for a simple Report Publication Announcement (RPA) and contains specific financial metrics, making ER the most appropriate classification. H1 2022
2022-07-22 German
Maria Soler Nunez appointed as Head, Group Operations
Board/Management Information Classification · 98% confidence The document is a press release dated July 1, 2022, announcing the appointment of Maria Soler Nunez as Head, Group Operations, and the retirement of Stefan Stoffel. This content directly relates to changes in senior management and the board structure. Based on the provided definitions, this fits the 'Board/Management Information' category (MANG). It is not a financial report (10-K, IR, ER), a shareholder vote result (DVA), or a general regulatory filing (RNS), as it is a specific personnel announcement.
2022-07-01 English
Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as an "Ad-hoc announcement pursuant to Art. 53 LR" and is released on 1 July 2022. It details a significant corporate action: Lonza's plan to invest CHF 500 million to establish a new commercial drug product fill & finish facility. This type of material, which announces major, price-sensitive corporate developments outside of routine periodic reporting (like 10-K or IR), is typically classified as a general regulatory announcement or a specific corporate action announcement. Since it is not a standard financial report (10-K, IR, ER), a management discussion (MDA), or a capital change (CAP/SHA), and it is a mandatory disclosure under listing rules (Art. 53 LR), it fits best under the general regulatory filing category, RNS, which serves as a fallback for mandatory, non-standard disclosures, or potentially as a Capital/Financing Update (CAP) due to the CHF 500M investment, but the primary nature is an operational/strategic update disclosed via ad-hoc rules. Given the options, RNS (Regulatory Filings) is the most appropriate catch-all for mandatory ad-hoc news releases that aren't explicitly covered elsewhere. It is not an announcement of a report (RPA), but the report itself.
2022-07-01 English
Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)
M&A Activity Classification · 99% confidence The document is explicitly titled 'Ad hoc announcement pursuant to Art. 53 LR' and is a press release dated July 1, 2022, detailing a major investment and expansion plan (building a new commercial drug product fill & finish facility). This type of announcement, which communicates significant, non-routine corporate news to the market immediately, is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the focus was purely on the CHF 500 million investment. However, since it is a broad strategic announcement released under specific listing rules (Art. 53 LR) and doesn't fit the specific definitions of 10-K, ER, or IR, RNS serves as the most appropriate general regulatory disclosure category for such ad hoc news releases that aren't covered by other specific codes like DIV or DIRS. Given the content is a strategic business update rather than a financial report, RNS is the best fit among the available options for a general regulatory disclosure.
2022-07-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.